What are the emerging indications for TAVI in 2025?

Tiffany Patterson, Nicolas Van Mieghem, and Philippe Généreux discuss emerging indications for TAVI in 2025. They review recent evidence on asymptomatic severe aortic stenosis, highlighting four randomised trials—RECOVERY, AVATAR, ONLY TAVR, and EVoLVeD—that show TAVI or surgical AVR reduces hospitalisations for heart failure and trends toward lower mortality and stroke compared to clinical surveillance.

The conversation then shifts to symptomatic moderate aortic stenosis, where the TAVR UNLOAD trial recently reported outcomes for patients with heart failure and reduced ejection fraction.

They also touch on ongoing studies such as PROGRESS and EXPAND II, and share insights on new devices for aortic regurgitation, with promising early data now progressing to randomised trials against surgery.

Don’t miss these key updates shaping TAVI’s expanding role.

This interview was filmed at EuroPCR 2025: see more videos here.